Page 4 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

Avoid Anti-HER2 Cancer Therapies During Pregnancy

Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates. ....

France General , Jean Philippe Spano , Paul Gougis , Daiichi Sakyo , World Health Organization , Institut Curie Centre De Recherche , Breast Cancer , Alignant Breast Neoplasm , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Her2 Positive Breast Cancer , Her2 Breast Cancer , Targeted Therapy , Alignant Neoplasia , Malignant Kidney Neoplasm , Kidney Cancer , Renal Cell Cancer , Enal Cell Ca ,

Lupus Drug Fails to Reduce Symptoms in Mid-stage Study

Roivant Sciences said on Monday its experimental drug to treat systemic lupus erythematosus failed to reduce symptoms of the autoimmune disease in a mid-stage study. ....

Pratik Jain , Eli Lilly , Shinjini Ganguli , Krishna Chandra Eluri , Roivant Sciences , Nektar Therapeutic , Systemic Lupus Erythematosus , Tyrosine Kinase Inhibitor , Biologic Therapy , Experimental Drug , Autoimmune Disease ,

FDA Approves Repotrectinib for ROS1-Positive NSCLC

The next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer. ....

United States , Jessicaj Lin , Bristol Myers Squibb , Drug Administration , Bristol Myers , Lung Cancer , Ung Carcinoma , Ancer Lung , Non Small Cell Lung Cancer , Biologic Therapy , Small Cell Lung Cancer , Nt Ears , Tyrosine Kinase Inhibitor , Alignant Neoplasia , Tyrosine Kinase , Aspiration Pneumonia , Peripheral Neuropathy ,

FDA Amends Pembrolizumab Indication in Gastric Cancer

The revised indication is based on recent findings from a prespecified interim analysis showing little benefit in patients whose tumors do not express PD-L1. ....

Drug Administration , Agilent Technologies , Noncolorectal Gastrointestinal Cancer , Oncolorectal Gi Cancer , Gastric Cancer , Alignant Stomach Neoplasm , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Alignant Neoplasia , Adenocarcinoma Gastroesophageal Junction , Us Food And Drug Ad ,

T-DXd Benefits Persist for HER2-Low Breast Cancer

Trastuzumab deruxtecan (T-DXd) provided sustained clinically meaningful improvement versus physician’s choice of treatment (TPC) for patients with advanced breast cancer and low HER2 expression. ....

New York , United States , Memorial Sloan Kettering Cancer Center , Giampaolo Bianchini , European Society Of Medical Oncology , Shanu Modi , European Society , Medical Oncology , San Raffaele , Breast Cancer , Alignant Breast Neoplasm , Metastatic Breast Carcinoma , Biologic Therapy , Alignant Neoplasia , Antineoplastic Drug , Nti Cancer Agents , Antibody Drug Conjugates Adcs , Oncological Medicine ,